More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$68.11B
EPS
13.47
P/E ratio
24
Price to sales
0.19
Dividend yield
0.74%
Beta
0.582965
Previous close
$359.03
Today's open
$362.59
Day's range
$355.90 - $363.50
52 week range
$244.82 - $377.54
show more
CEO
Robert P. Mauch
Employees
51000
Headquarters
Conshohocken, PA
Exchange
New York Stock Exchange
Shares outstanding
190827165
Issue type
Common Stock
Healthcare
Medical Distributors
Nike Among 13 Dividend Growth Companies To Announce Annual Dividend Increases In Latter Half Of November
I expect Nike (NKE) to raise its dividend 1.2–2.4%, as weak sales, flat EPS and a payout ratio around 80% constrain growth. Matthews International (MATW) risks a dividend cut; Hormel (HRL) faces an above-100% payout ratio and likely will increase its annual dividend just one cent. Motorola Solutions (MSI) should deliver a 10%+ increase, while Marzetti (MZTI) is poised to extend its 63-year streak with a roughly 5% boost.
Seeking Alpha • Nov 16, 2026

US FTC sues to block Cencora's $3.5 billion sale of veterinary unit to Covetrus
The US antitrust regulator filed a lawsuit on Friday in a New York federal court to block Cencora's $3.5 billion sale of its MWI Animal Health unit to veterinary supplier Covetrus, arguing the deal would raise costs for clinics and pet owners.
Reuters • Nov 13, 2026

Dividend Announcements: October 31-November 6, 2026 (Part 2 Of 2)
I monitor dividend increases and cuts across 1,200+ stocks, focusing on dividend growth streaks, safety, and valuation to identify high-conviction opportunities. In this second article in two parts, I highlight 17 Dividend Contenders and 2 special dividends this week. Snap-on (SNA) stands out with a 12.7% dividend hike, 17-year streak, 7.68 Quality Score, and top-tier dividend safety.
Seeking Alpha • Nov 9, 2026

3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility
BDX, COR and UNF recently hiked dividends, offering investors steady income opportunities as market volatility, inflation and economic uncertainty persist.
Zacks Investment Research • Nov 6, 2026

What Cencora (COR) Said on Its Q4 Earnings Call
Cencora NYSE: COR reported higher fiscal fourth-quarter revenue and adjusted earnings as specialty drug sales and its acquisition of OneOncology contributed to growth. The company also introduced a new reporting structure that separates its specialty operations from its broader pharmaceutical distribution business.
MarketBeat • Nov 5, 2026

Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript
Cencora, Inc. (COR) Q4 2026 Earnings Call Transcript
Seeking Alpha • Nov 4, 2026

Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion. Revenue increased 5.0 percent to $337.4 billion for fiscal year 2026. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.71 for the fourth quarter of fiscal 2026, compared to $(1.75) in the prior year quarter. Adjusted diluted EPS, which is a no.
Business Wire • Nov 4, 2026

Cencora (COR) Surpasses Q4 Earnings and Revenue Estimates
Cencora (COR) came out with quarterly earnings of $4.66 per share, beating the Zacks Consensus Estimate of $4.56 per share. This compares to earnings of $3.84 per share a year ago.
Zacks Investment Research • Nov 4, 2026

Cencora (COR) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 4, 2026

Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand
COR's Q4 earnings and revenues beat estimates as specialty drug demand fuels growth and margins expand. The company raises its fiscal 2027 outlook.
Zacks Investment Research • Nov 4, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Cencora Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.